Skip to main content

Ryan Arthur F's Form 4 filing

Regeneron Pharmaceuticals, Inc. (REGN) · filed Apr 3, 2024

Accession no.
0001968202-24-000090
Filed
Apr 3, 2024
Trade date
Apr 1, 2024
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 9 non-derivative transactions. Open-market sales total $96.3K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Ryan Arthur FCIK 0001187443Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 1, 2024Common StockSSaleDisposed−2$957.78−$1,915.5618,280Direct
Apr 1, 2024Common StockSSaleDisposed−2$958.86−$1,917.7218,278Direct
Apr 1, 2024Common StockSSaleDisposed−9$959.47F2−$8,635.2318,269Direct
Apr 1, 2024Common StockSSaleDisposed−15$960.53F3−$14,407.9518,254Direct
Apr 1, 2024Common StockSSaleDisposed−14$961.59F4−$13,462.2618,240Direct
Apr 1, 2024Common StockSSaleDisposed−9$962.42F5−$8,661.7818,231Direct
Apr 1, 2024Common StockSSaleDisposed−20$963.60F6−$19,27218,211Direct
Apr 1, 2024Common StockSSaleDisposed−16$964.45F7−$15,431.218,195Direct
Apr 1, 2024Common StockSSaleDisposed−13$965.35F8−$12,549.5518,182Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents volume-weighted average price of sales of 9 shares of Company stock on April 1, 2024 at prices ranging from $959.13 to $959.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2024 at each separate price.

Referenced by the price of 1 transaction in Table I.

F3

Represents volume-weighted average price of sales of 15 shares of Company stock on April 1, 2024 at prices ranging from $960.06 to $960.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2024 at each separate price.

Referenced by the price of 1 transaction in Table I.

F4

Represents volume-weighted average price of sales of 14 shares of Company stock on April 1, 2024 at prices ranging from $961.10 to $961.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2024 at each separate price.

Referenced by the price of 1 transaction in Table I.

F5

Represents volume-weighted average price of sales of 9 shares of Company stock on April 1, 2024 at prices ranging from $962.06 to $962.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2024 at each separate price.

Referenced by the price of 1 transaction in Table I.

F6

Represents volume-weighted average price of sales of 20 shares of Company stock on April 1, 2024 at prices ranging from $963.02 to $963.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2024 at each separate price.

Referenced by the price of 1 transaction in Table I.

F7

Represents volume-weighted average price of sales of 16 shares of Company stock on April 1, 2024 at prices ranging from $964.02 to $964.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2024 at each separate price.

Referenced by the price of 1 transaction in Table I.

F8

Represents volume-weighted average price of sales of 13 shares of Company stock on April 1, 2024 at prices ranging from $965.00 to $965.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2024 at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)